Initial Statement of Beneficial Ownership (3)
June 05 2020 - 7:53PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
BEN-MAIMON CAROLE |
2. Date of Event Requiring Statement (MM/DD/YYYY)
5/28/2020
|
3. Issuer Name and Ticker or Trading Symbol
Larimar Therapeutics, Inc. [LRMR]
|
|
(Last)
(First)
(Middle)
C/O LARIMAR THERAPEUTICS, INC., THREE BALA PLAZA EAST, SUITE 506 |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__X__ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
President and CEO / |
|
(Street)
BALA CYNWYD, PA 19004
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4) | 2. Amount of Securities Beneficially Owned
(Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) | 4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4) | 2. Date Exercisable and Expiration Date
(MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) | 6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Option (Right to Buy) | (1) | 5/28/2029 | Common Stock | 133140 | $11.73 | D | |
| Stock Option (Right to Buy) | (2) | 4/10/2027 | Common Stock | 61419 | $11.73 | D | |
| Explanation of Responses: |
| (1) | 25% of the Stock Options became exercisable immediately, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. |
| (2) | 37,107 Stock Options became exercisable immediately, and the remaining 8,957 Stock Options will become exercisable in equal monthly installments on the last day of each of the 7 months immediately following such date, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
BEN-MAIMON CAROLE
C/O LARIMAR THERAPEUTICS, INC.
THREE BALA PLAZA EAST, SUITE 506
BALA CYNWYD, PA 19004 | X |
| President and CEO |
|
Signatures
|
| /s/ Jennifer Johansson, Attorney-in-fact | | 6/5/2020 |
| **Signature of Reporting Person | Date |
Zafgen (NASDAQ:ZFGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zafgen (NASDAQ:ZFGN)
Historical Stock Chart
From Apr 2023 to Apr 2024
